A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer
• Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements；
• The age of signing the informed consent is 18 -70 years, regardless of gender；
• Provide archived or fresh tumor tissue for vendor test;
• At least one measurable lesion according to RECIST v1.1 criteria；
• Subjects with pathology confirmed locally advanced unresectable or metastatic non-small cell lung squamous cell carcinoma;
• The ECOG score is 0 or 1；
• Expected survival ≥12 weeks
• Good level of organ function
• Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.